Prof. Dr. med. Jakob R. Passweg

Meier-Lienhard, R., Suter, C., Pabst, T., Hitz, F., Passweg, J. R., Spertini, O., Cantoni, N., Betticher, D., Simeon, L., Medinger, M., Hayoz, S., & Schmidt, A. (2025). Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature [Journal-article]. Swiss Medical Weekly, 155(1), 3885. https://doi.org/10.57187/s.3885

Passweg, J. R., Baldomero, H., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A., Ciceri, F., Raffaella, G., Hazenberg, M. D., Kalwak, K., McLornan, D. P., Risitano, A. M., Ruggeri, A., Snowden, J. A., & Sureda, A. (2024). Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT [Journal-article]. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02459-0

Arber, C., Baerlocher, G., Chalandon, Y., Daskalakis, M., Duchosal, M., Fehr, M., Gerull, S., Güngör, T., Nair, G., Pabst, T., Passweg, J. R., Piccolruaz, B., Renner, C., Ruefer, A., Schneidawind, D., Stüssi, G., Zeerleder, S., & Halter, J. P. (2024). Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Medical Weekly, 154(10). https://doi.org/10.57187/s.3704

Atsuta, Y., Baldomero, H., Neumann, D., Sureda, A., DeVos, J. D., Iida, M., Karduss, A., Purtill, D., Elhaddad, A. M., Bazuaye, N. G., Bonfim, C., de la Camara, R., Chaudhri, N. A., Ciceri, F., Correa, C., Frutos, C., Galeano, S., Garderet, L., Gonzalez-Ramella, O., et al. (2024). Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica, 109(10), 3282–3294. https://doi.org/10.3324/haematol.2024.285002

Chalandon, Y., Eikema, D.-J., Moiseev, I., Ciceri, F., Koster, L., Vydra, J., Passweg, J., Rovira, M., Ozcelik, T., Gedde-Dahl, T., Kröger, N., Potter, V., Yakoub-Agha, I., Rambaldi, A., Itälä-Remes, M., Tanase, A., Onida, F., Gurnari, C., Scheid, C., et al. (2024). Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Advances, 8(18), 4792–4802. https://doi.org/10.1182/bloodadvances.2024013468

Garderet, L., Gras, L., Koster, L., de Wreede, L., Montserrat, R., Vincent, L., Fenk, R., Karunanithi, K., Deeren, D., Kaufmann, M., Kuball, J., Ozdogu, H., Cascon, M. J. P., Passweg, J., Rye, A., Salmenniemi, U., Snowden, J., Hansen, C. T., Leleu, X., et al. (2024). Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 109(8), 2619–2627. https://doi.org/10.3324/haematol.2023.284520

Penack, O., Abouqateb, M., Peczynski, C., Boreland, W., Kröger, N., Zeiser, R., Ciceri, F., Schroeder, T., Dreger, P., Passweg, J., Schetelig, J., Stelljes, M., Blau, I. W., Franke, G.-N., Riesner, K., Schoemans, H., Moiseev, I., & Peric, Z. (2024). How risky is a second allogeneic stem cell transplantation? [Journal-article]. Leukemia. https://doi.org/10.1038/s41375-024-02318-3

Baldomero, H., Neumann, D., Hamad, N., Atsuta, Y., Sureda, A., Iida, M., Karduss, A., Elhaddad, A. M., Bazuaye, N. G., Bonfim, C., Camara, R. d. l., Chaudhri, N. A., Ciceri, F., Correa, C., Frutos, C., Galeano, S., Garderet, L., Greco, R., Jaimovich, G., et al. (2024). The role of registries in hematological disorders. Best Practice and Research: Clinical Haematology, 37(2). https://doi.org/10.1016/j.beha.2024.101556

Scheid, C., Eikema, D.-J., Van Gelder, M., Salmenniemi, U., Maertens, J., Passweg, J. R., Blaise, D., Byrne, J. L., Kroeger, N., Sockel, K., Chevallier, P., Bourhis, J. H., Cornelissen, J. J., Sengeloev, H., Finke, J., Snowden, J. A., Gedde-Dahl, T., cornillon, j., Schanz, U., et al. (2024). Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms? [Journal-article]. Blood Journal. https://doi.org/10.1182/blood.2023022273

Gurnari, C., Koster, L., Baaij, L., Heiblig, M., Yakoub-Agha, I., Collin, M., Passweg, J., Bulabois, C. E., Khan, A., Loschi, M., Carnevale-Schianca, F., Crisà, E., Caravelli, D., Kuball, J., Saraceni, F., Olivieri, A., Rambaldi, A., Kulasekararaj, A. G., Hayden, P. J., et al. (2024). Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Advances, 8(6), 1444–1448. https://doi.org/10.1182/bloodadvances.2023012478

Sadowska-Klasa, A., Zaucha, J.M., Labopin, M., Bourhis, J.H., Blaise, D., Yakoub-Agha, I., Salmenniemi, U., Passweg, J., Fegueux, N., Schroeder, T., Giebel, S., Brissot, E., Ciceri, F., & Mohty, M. (2024). Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry. Bone Marrow Transplantation, 59(3), 387–394. https://doi.org/10.1038/s41409-023-02192-0

Manuel, Oriol, Laager, Mirjam, Hirzel, Cédric, Neofytos, Dionysios, Walti, Laura N, Hoenger, Gideon, Binet, Isabelle, Schnyder, Aurelia, Stampf, Susanne, Koller, Michael, Mombelli, Matteo, Kim, Min Jeong, Hoffmann, Matthias, Koenig, Katrin, Hess, Christoph, Burgener, Anne-Valérie, Cippà, Pietro E, Hübel, Kerstin, Mueller, Thomas F, et al. (2024). Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial [Journal-article]. Clinical Infectious Diseases, 78(2), 312–323. https://doi.org/10.1093/cid/ciad575

Codilupi, Tamara, Szybinski, Jakub, Arunasalam, Stefanie, Jungius, Sarah, Dunbar, Andrew C., Stivala, Simona, Brkic, Sime, Albrecht, Camille, Vokalova, Lenka, Yang, Julie L., Buczak, Katarzyna, Ghosh, Nilabh, Passweg, Jakob R., Rovo, Alicia, Angelillo-Scherrer, Anne, Pankov, Dmitry, Dirnhofer, Stefan, Levine, Ross L., Koche, Richard, & Meyer, Sara C. (2024). Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable [Journal-article]. Clinical Cancer Research, 30(3), 586–599. https://doi.org/10.1158/1078-0432.ccr-23-0163

Stivala, Simona, Codilupi, Tamara, Dirnhofer, Stefan, Koche, Richard, Passweg, Jakob R., Pankov, Dmitry, Meyer, Sara C., Szybinski, Jakub, Arunasalam, Stefanie, Jungius, Sarah, Dunbar, Andrew C., Brkic, Sime, Albrecht, Camille, Ghosh, Nilabh, Rovo, Alicia, Angelillo-Scherrer, Anne, Vokalova, Lenka, Levine, Ross L., Yang, Julie L., & Buczak, Katarzyna. (2024). Data from Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable [Posted-content]. American Association for Cancer Research (AACR). https://doi.org/10.1158/1078-0432.c.7054101.v1

Bader, Michael Stephan, Kubetzko, Susanne, Schäfer, Beat Werner, Arranto, Christian, Drexler, Beatrice, Halter, Jörg, Passweg, Jakob R., & Medinger, Michael. (2024). Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05943-1

Baldrich, Adrian, Althaus, Dominic, Menter, Thomas, Hirsiger, Julia R., Köppen, Julius, Hupfer, Robin, Juskevicius, Darius, Konantz, Martina, Bosch, Angela, Drexler, Beatrice, Gerull, Sabine, Ghosh, Adhideb, Meyer, Benedikt J., Jauch, Annaise, Pini, Katia, Poletti, Fabio, Berkemeier, Caroline M., Heijnen, Ingmar, Panne, Isabelle, et al. (2024). Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency. Journal of Clinical Immunology, 44. https://doi.org/10.1007/s10875-024-01667-z

Ben Hassine, Khalil, Seydoux, Claire, Khier, Sonia, Daali, Youssef, Medinger, Michael, Halter, Joerg, Heim, Dominik, Chalandon, Yves, Schanz, Urs, Nair, Gayathri, Cantoni, Nathan, Passweg, Jakob R., Satyanarayana Uppugunduri, Chakradhara Rao, & Ansari, Marc. (2024). Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT. Transplantation and Cellular Therapy, null. https://doi.org/10.1016/j.jtct.2023.12.003

Goldin, Ilja, Medinger, Michael, Passweg, Jakob, & Halbeisen, Delia. (2024). A Patient with Acute Promyelocytic Leukemia Treated with Isotretinoin: A Case Report [Journal-article]. Case Reports in Oncology, 17(1), 1103–1108. https://doi.org/10.1159/000541328

Guièze, R., Eikema, D.-J., Koster, L., Schetelig, J., Sengeloev, H., Passweg, J., Finke, J., Arat, M., Broers, A. E. C., Stölzel, F., Byrne, J., Castilla-Llorente, C., Dreger, P., Eder, M., Gedde-Dahl, T., Kröger, N., Ribera Santasusana, J. M., Richardson, D., Rambaldi, A., et al. (2024). Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02256-9

Heim, Dominik, Baldomero, Helen, Medinger, Michael, Masouridi-Levrat, Stavroula, Schanz, Urs, Nair, Gayathri, Güngör, Tayfun, Halter, Jörg, Passweg, Jakob R., & Chalandon, Yves. (2024). Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs. Swiss Medical Weekly, 154. https://doi.org/10.57187/s.3754

Infanti, Laura, Leitner, Gerda, Moe, Morten, Pehlic, Vildana, Cattaneo, Marco, Benkert, Pascal, Holbro, Andreas, Passweg, Jakob, Worel, Nina, & Buser, Andreas. (2024). Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1362941

Janscak, Marie, Stelmes, Anne, van den Berg, Jana, Heim, Dominik, Halter, Joerg, Drexler, Beatrice, Arranto, Christian, Passweg, Jakob, & Medinger, Michael. (2024). Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation [Journal-article]. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02395-z

Jauch, Annaïse J., Alborelli, Ilaria, Reusser, Andreas, Baschong, Albert, Rütsche, Cyrill, Bignucolo, Olivier, Passweg, Jakob, Dirnhofer, Stefan, & Krasniqi, Fatime. (2024). Case report: ‘Atypical Richter transformation from CLL-type monoclonal B-cell lymphocytosis into Burkitt lymphoma in a treatment naïve patient’. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1296238

König, David, Sandholzer, Michael T., Uzun, Sarp, Zingg, Andreas, Ritschard, Reto, Thut, Helen, Glatz, Katharina, Kappos, Elisabeth A., Schaefer, Dirk J., Kettelhack, Christoph, Passweg, Jakob R., Holbro, Andreas, Baur, Katharina, Medinger, Michael, Buser, Andreas, Lardinois, Didier, Jeker, Lukas T., Khanna, Nina, Stenner, Frank, et al. (2024). Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 12, 814–821. https://doi.org/10.1158/2326-6066.CIR-23-0757

König, D., Kasenda, B., Sandholzer, M., Chirindel, A., Zingg, A., Ritschard, R., Thut, H., Glatz, K., Kappos, E.A., Schaefer, D., Kettelhack, C., Passweg, J., Baur, K., Holbro, A., Buser, A., Lardinois, D., Jeker, L.T., Khanna, N., Stenner, F., et al. (2024). Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma. Immuno-Oncology and Technology. https://doi.org/10.1016/j.iotech.2024.100728

Kusejko, Katharina, Neofytos, Dionysios, Van Delden, C., Hirsch, H.H., Meylan, Pascal, Boggian, Katia, Hirzel, Cedric, Garzoni, C., Sidler, Daniel, Schnyder, A., Schaub, Stefan, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D., Mueller, N.J., Schreiber, Peter W., Amico, P., Aubert, J.-D., et al. (2024). Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation? [Journal-article]. Open Forum Infectious Diseases, 11(3). https://doi.org/10.1093/ofid/ofae055

Loke, Justin, Labopin, Myriam, Craddock, Charles, Socié, Gérard, Gedde-Dahl, Tobias, Blaise, Didier, Forcade, Edouard, Salmenniemi, Urpu, Huynh, Anne, Versluis, Jurjen, Yakoub-Agha, Ibrahim, Labussière-Wallet, Hélène, Maertens, Johan, Passweg, Jakob, Bulabois, Claude Eric, Gabellier, Ludovic, Mielke, Stephan, Castilla-Llorente, Cristina, Deconinck, Eric, et al. (2024). Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study. Cancer. https://doi.org/10.1002/cncr.35308

Maffini, Enrico, Labopin, Myriam, Kröger, Nicolaus, Finke, Jürgen, Stelljes, Matthias, Schroeder, Thomas, Einsele, Herman, Tischer, Johanna, Bornhäuser, Martin, Bethge, Wolfgang, Brecht, Arne, Rösler, Wolf, Dreger, Peter, Schäfer-Eckart, Kerstin, Passweg, Jakob, Blau, Igor Wolfgang, Nagler, Arnon, Ciceri, Fabio, & Mohty, Mohamad. (2024). Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02275-6

Montoro, Juan, Eikema, Dirk-Jan, Tuffnell, Joe, Potter, Victoria, Kalwak, Krzysztof, Halkes, Constantijn J. M., Kulagin, Alexander, Collin, Matthew, Wynn, Robert F., Robinson, Stephen, Nicholson, Emma, Sengeloev, Henrik, Clay, Jennifer, Halahleh, Khalid, Skorobogatova, Elena, Sanz, Jaime, Passweg, Jakob, Mielke, Stephan, Ryhänen, Samppa, et al. (2024). Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT. Blood. https://doi.org/10.1182/blood.2024024173

Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Schroeder, Thomas, Hamladji, Rose-Marie, Griskevicius, Laimonas, Salmenniemi, Urpu, Rambaldi, Alessandro, Mielke, Stephan, Kulagin, Alexander, Passweg, Jakob, Luft, Thomas, Gedde-Dahl, Tobias, Forcade, Edouard, Helbig, Grzegorz, Stelljes, Matthias, Castilla-Llorente, Cristina, Spyridonidis, Alexandros, Brissot, Eolia, et al. (2024). Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02284-5

Niederwieser, Christian, Iacobelli, Simona, Franke, Georg-Nikolaus, Koster, Linda, van Os, Marleen, Platzbecker, Uwe, Hübel, Kai, Scheid, Christof, Müller, Lutz Peter, Stelljes, Matthias, Morozova, Elena, Passweg, Jakob, Onida, Francesco, Dreger, Peter, Saccardi, Riccardo, Ladetto, Marco, Salmenniemi, Urpu, Bethge, Wolfgang, Poiré, Xavier, et al. (2024). Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02282-7

Onida, Francesco, Gras, Luuk, Ge, Junran, Koster, Linda, Hamladji, Rose-Marie, Byrne, Jenny, Avenoso, Daniele, Aljurf, Mahmoud, Robin, Marie, Halaburda, Kazimierz, Passweg, Jakob, Salmenniemi, Urpu, Sengeloev, Henrik, Apperley, Jane, Clark, Andrew, Reményi, Péter, Morozova, Elena, Kinsella, Francesca, Lenhoff, Stig, et al. (2024). Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology, 204, 2365–2377. https://doi.org/10.1111/bjh.19448

Passweg, Jakob R., Baldomero, Helen, Ansari, Marc, Arber, Caroline, Chalandon, Yves, Daskalakis, Michael, Diepold, Miriam, Diesch-Furlanetto, Tamara, Duchosal, Michel A., Gerull, Sabine, Güngör, Tayfun, Heim, Dominik, Hitz, Felicitas, Holbro, Andreas, Masouridi-Levrat, Stavroula, Nair, Gayathri, Novak, Urban, Pabst, Thomas, Renner, Christoph, et al. (2024). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021. Hematological Oncology, 42. https://doi.org/10.1002/hon.3241

Passweg, J. R., Baldomero, H., Ciceri, F., de la Cámara, R., Glass, B., Greco, R., Hazenberg, M. D., Kalwak, K., McLornan, D. P., Neven, B., Perić, Z., Risitano, A. M., Ruggeri, A., Snowden, J. A., & Sureda, A. (2024). Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02248-9

Penack, Olaf, Marchetti, Monia, Aljurf, Mahmoud, Arat, Mutlu, Bonifazi, Francesca, Duarte, Rafael F, Giebel, Sebastian, Greinix, Hildegard, Hazenberg, Mette D, Kröger, Nicolaus, Mielke, Stephan, Mohty, Mohamad, Nagler, Arnon, Passweg, Jakob, Patriarca, Francesca, Ruutu, Tapani, Schoemans, Hélène, Solano, Carlos, Vrhovac, Radovan, et al. (2024). Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology, 11, e147–e159. https://doi.org/10.1016/S2352-3026(23)00342-3

Polverelli, Nicola, Bonneville, Edouard F., de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus Martin, Schroeder, Thomas, Peffault de Latour, Régis, Passweg, Jakob, Sockel, Katja, Broers, Annoek E. C., Clark, Andrew, Dreger, Peter, Blaise, Didier, Yakoub-Agha, Ibrahim, Petersen, Soeren Lykke, Finke, Jürgen, Chevallier, Patrice, Helbig, Grzegorz, Rabitsch, Werner, et al. (2024). Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. American Journal of Hematology, 99, 993–996. https://doi.org/10.1002/ajh.27262

Rafii, Hanadi, Volt, Fernanda, Bierings, Marc, Dalle, Jean-Hugues, Ayas, Mouhab, Rihani, Rawad, Faraci, Maura, de Simone, Giuseppina, Sengeloev, Henrik, Passweg, Jakob, Cavazzana, Marina, Costello, Regis, Maertens, Johan, Biffi, Alessandra, Johansson, Jan-Erik, Montoro, Juan, Guepin, Gabrielle Roth, Diaz, Miguel Angel, Sirvent, Anne, et al. (2024). Umbilical Cord Blood Transplantation for Fanconi Anemia With a Special Focus on Late Complications: a Study on Behalf of Eurocord and SAAWP-EBMT. Transplantation and Cellular Therapy, 30, 532. https://doi.org/10.1016/j.jtct.2024.02.024

Robin, M., Iacobelli, S., Koster, L., Passweg, J., Avenoso, D., Wilson, K. M. O., Salmenniemi, U., Dreger, P., von dem Borne, P., Snowden, J. A., Robinson, S., Finazzi, M. C., Schroeder, T., Collin, M., Eder, M., Forcade, E., Loschi, M., Bramanti, S., Pérez-Simón, J. A., et al. (2024). Correction to: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT (Bone Marrow Transplantation, (2024), 10.1038/s41409-024-02269-4). Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02293-4

Robin, Marie, Iacobelli, Simona, Koster, Linda, Passweg, Jakob, Avenoso, Daniele, Wilson, Keith M. O., Salmenniemi, Urpu, Dreger, Peter, von dem Borne, Peter, Snowden, John A., Robinson, Stephen, Finazzi, Maria Chiara, Schroeder, Thomas, Collin, Matthew, Eder, Matthias, Forcade, Edouard, Loschi, Michael, Bramanti, Stefania, Pérez-Simón, Jose Antonio, et al. (2024). Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02269-4

Salas, María Queralt, Eikema, Diderik-Jan, Koster, Linda, Maertens, Johan, Passweg, Jakob, Finke, Jürgen, Broers, Annoek E. C., Koc, Yener, Kröger, Nicolaus, Ozkurt, Zubeyde Nur, Pascual-Cascon, María Jesús, Platzbecker, Uwe, Van Gorkom, Gwendolyn, Schroeder, Thomas, López-Lorenzo, José Luis, Martino, Massimo, Chiusolo, Patrizia, Kaufmann, Martin, Onida, Francesco, et al. (2024). Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, null. https://doi.org/10.1038/s41409-023-02159-1

Schreiber, Peter W., Hoessly, Linard, Boggian, Katia, Neofytos, Dionysios, van Delden, Christian, Egli, Adrian, Dickenmann, Michael, Hirzel, Cédric, Manuel, Oriol, Koller, Michael, Rossi, Simona, Banz, Vanessa, Schmied, Bruno, Guerke, Lorenz, Matter, Maurice, de Rougemont, Olivier, Bonani, Marco, Golshayan, Déla, Schnyder, Aurelia, et al. (2024). Surgical site infections after kidney transplantation are independently associated with graft loss. American Journal of Transplantation, 24, 795–802. https://doi.org/10.1016/j.ajt.2023.11.013

Seydoux, Claire, Uppugunduri, Chakradhara Rao Satyanarayana, Medinger, Michael, Nava, Tiago, Halter, Joerg, Heim, Dominik, Chalandon, Yves, Schanz, Urs, Nair, Gayathri, Cantoni, Nathan, Passweg, Jakob R., & Ansari, Marc. (2024). Correction to: Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan (Bone Marrow Transplantation, (2023), 58, 7, (811-816), 10.1038/s41409-023-01963-z). Bone Marrow Transplantation, 59, 294. https://doi.org/10.1038/s41409-023-02166-2

Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, Duarte RF, Schroeder T, Passweg J, Wulf GG, Ganser A, Sica S, Arat M, Salmenniemi U, Broers AEC, et al. (2023). Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplantation, 58(11), 1209–1214. https://doi.org/10.1038/s41409-023-02077-2

Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, & Cloos J. (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica, 108(10), 2794–2798. https://doi.org/10.3324/haematol.2022.282639

McLornan, D., Salas, M., Eikema, D.-J., Koster, L., Maertens, J., Passweg, J., Finke, J., Broers, A., Koc, Y., Kroeger, N., Ozkurt, Z., Pascual, M., Platzbecker, U., Gorkom, G. V., Schroeder, T., Lorenzo, J. L., Martino, M., Chiusolo, P., Kaufmann, M., et al. (2023). Impact of Post-transplant cyclophosphamide (PTCy)-Based Prophylaxis in Matched Sibling Donor Allogeneic Haematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT [Posted-content]. Research Square Platform LLC. https://doi.org/10.21203/rs.3.rs-3286332/v1

Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, et al. (2023). Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 58(7), 784–790. https://doi.org/10.1038/s41409-023-01961-1

Dertschnig S, Passweg J, Bucher C, Medinger M, Medinger M, & Tzankov A. (2023). Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation. Cellular Immunology, 388-389, 104719. https://doi.org/10.1016/j.cellimm.2023.104719

Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, Socié G, van Gorkom G, Labussière-Wallet H, Huang XJ, Rubio MT, Byrne J, Craddock C, Griškevičius L, Ciceri F, & Mohty M. (2023). Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation, 58(7), 791–800. https://doi.org/10.1038/s41409-023-01980-y

Seydoux C, Uppugunduri CRS, Medinger M, Nava T, Halter J, Heim D, Chalandon Y, Schanz U, Nair G, Cantoni N, Passweg JR, & Ansari M. (2023). Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan. Bone Marrow Transplantation, 58(7), 811–816. https://doi.org/10.1038/s41409-023-01963-z

Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour RP, Byrne J, Krüger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, et al. (2023). Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience (Patent No. 6). 108(6), Article 6. https://doi.org/10.3324/haematol.2022.281754

Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, de Latour RP, Perić Z, Ruggeri A, Snowden JA, & Sureda A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58(6), 647–658. https://doi.org/10.1038/s41409-023-01943-3

Saccardi R, Putter H, Eikema DJ, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari AMS, Chabannon C, Corbacioglu S, Dolstra H, Duarte RF, Dulery R, et al. (2023). Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 58(6), 659–666. https://doi.org/10.1038/s41409-023-01924-6

Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, van de Loosdrecht AA, Maertens JA, et al. (2023). Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial. Blood, 141(21), 2657–2661. https://doi.org/10.1182/blood.2022019160

Rai, S., Zhang, Y., Grockowiak, E., Kimmerlin, Q., Hansen, N., Stoll, C. B., Usart, M., Hao-Shen, H., Bader, M. S., Passweg, J. R., Dirnhofer, S., Farady, C. J., Schroeder, T., Méndez-Ferrer, S., & Skoda, R. C. (2023). IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2 -mutant hematopoietic stem cells [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2023.05.21.541610

Greco R, Hoogenboom JD, Bonneville EF, Anagnostopoulos A, Cuoghi A, Dalle JH, Weissinger EM, Lang P, Galaverna F, Martino M, Maschan A, Mauz-Körholz C, Noviello M, Passweg J, Peccatori J, Rovira M, Solano C, Veelken H, Velardi A, et al. (2023). Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party (Patent No. 5). 58(5), Article 5. https://doi.org/10.1038/s41409-023-01939-z

Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kröger N, Dreger P, Besley C, Schanz U, Bloor A, Ganser A, Forcade E, Corral LL, Passweg JR, Novak U, Moiseev I, Schoemans H, et al. (2023). Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer, 11(4). https://doi.org/10.1136/jitc-2022-006406

Robin M, de Wreede LC, Schroeder T, Stölzel F, Kröger N, Koster L, Platzbecker U, Finke J, Ganser A, Blaise D, Ciceri F, Maertens J, Labussière Wallet H, Wang J, Chevallier P, Passweg J, Cornelissen JJ, Nguyen S, Forcade E, et al. (2023). Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT. HemaSphere, 7(4), e851. https://doi.org/10.1097/HS9.0000000000000851

Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBC, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss AJ, Ciceri F, Colturato VAR, Corbacioglu S, Elhaddad A, Force LM, Frutos C, León AG, et al. (2023). An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 29(4), 279. https://doi.org/10.1016/j.jtct.2022.12.013

Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MA, Passweg J, Byrne J, Ho A, Huang XJ, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan DP, Onida F, Scheid C, et al. (2023). Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT (Patent No. 2). 58(2), Article 2. https://doi.org/10.1038/s41409-022-01870-9

Rebmann E, Nabergoj M, Grandjean B, Stakia P, Stern A, Medinger M, Masouridi-Levrat S, Dantin C, Schanz U, Baldomero H, Passweg J, Nair G, Rovo A, & Chalandon Y. (2023). Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better. EJHaem, 4(1), 258–261. https://doi.org/10.1002/jha2.614

Simeunovic H, Dickenmann M, Nabergoj M, Baldomero H, Masouridi-Levrat S, Nair G, Schanz U, Passweg J, Rovo A, Chalandon Y, & Rebmann E. (2023). Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001-2020. EJHaem, 4(1), 262–265. https://doi.org/10.1002/jha2.629

Bänziger S, Weisshaar K, Arokoski R, Gerull S, Halter J, Rovó A, Bargetzi M, Goede JS, Senft Y, Valenta S, Passweg JR, & Drexler B. (2023). Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria—a pilot study (ePRO-AA-PNH). Annals of Hematology, 102(1), 199–208. https://doi.org/10.1007/s00277-022-05012-5

Baur, Katharina, Buser, Andreas, Jeker, Lukas T., Khanna, Nina, Läubli, Heinz, Heim, Dominik, Dirks, Jan C., Widmer, Corinne C., Volken, Thomas, Passweg, Jakob R., & Holbro, Andreas. (2023). CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas. Bone Marrow Transplantation, 58, 1048–1050. https://doi.org/10.1038/s41409-023-02016-1

Capoferri, Gioele, Walti, Carla Simone, Urwyler, Pascal, Ragozzino, Silvio, Passweg, Jakob R., Halter, Jörg, Battegay, Manuel, Baettig, Veronika, Weisser, Maja, Arnold, Brice, Morin, Benedict, Guetlin, Yukino, Torres, Diana Albertos, Barut, Güliz Tuba, Thiel, Volker, Egli, Adrian, Drexler, Beatrice, & Khanna, Nina. (2023). Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 58(5), 597–599. https://doi.org/10.1038/s41409-023-01936-2

Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, et al. (2023). Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. American Journal of Hematology, 98(1), 112–121. https://doi.org/10.1002/ajh.26764

Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, Stylianou C, Oehen S, Heim D, & Bucher C. (2023). Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplantation and Cellular Therapy, 29(1), 41. https://doi.org/10.1016/j.jtct.2022.10.029

Griessbach, Alexandra, Chammartin, Frédérique, Abela, Irene A., Amico, Patrizia, Stoeckle, Marcel P., Eichenberger, Anna L., Hasse, Barbara, Braun, Dominique L., Schuurmans, Macé M., Müller, Thomas F., Tamm, Michael, Audigé, Annette, Mueller, Nicolas J., Rauch, Andri, Günthard, Huldrych F., Koller, Michael T., Trkola, Alexandra, Epp, Selina, Amstutz, Alain, et al. (2023). Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2). Open Forum Infectious Diseases, 10. https://doi.org/10.1093/ofid/ofad536

Jungius, Sarah, Adam, Franziska C., Grosheintz, Kerstin, Medinger, Michael, Buser, Andreas, Passweg, Jakob R., Halter, Jörg P., & Meyer, Sara C. (2023). Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1205387

Junker, Till, Volken, Thomas, Stehle, Gregor, Drexler, Beatrice, Infanti, Laura, Buser, Andreas, Passweg, Jakob, Schaub, Stefan, Dickenmann, Michael, Halter, Jörg, & Holbro, Andreas. (2023). Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study. Transfusion Medicine and Hemotherapy, 50, 76–87. https://doi.org/10.1159/000528261

Luque Paz, Damien, Bader, Michael S., Nienhold, Ronny, Rai, Shivam, Almeida Fonseca, Tiago, Stetka, Jan, Hao-Shen, Hui, Mild-Schneider, Gabriele, Passweg, Jakob R., & Skoda, Radek C. (2023). Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms. HemaSphere, 7(5), E885. https://doi.org/10.1097/hs9.0000000000000885

Nassani M, Fakih RE, Passweg J, Cesaro S, Alzahrani H, Alahmari A, Bonfim C, Iftikhar R, Albeihany A, Halkes C, Ahmed SO, Dufour C, & Aljurf M. (2023). The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes. Frontiers in Oncology, 13, 1135160. https://doi.org/10.3389/fonc.2023.1135160

Ragozzino, Silvio, Mueller, Nicolas J., Neofytos, Dionysios, Passweg, Jakob, Müller, Antonia, Medinger, Michael, Van Delden, Christian, Masouridi-Levrat, Stavroula, Chalandon, Yves, Tschudin-Sutter, Sarah, Khanna, Nina, & Van Delden, Christian. (2023). Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation: a longitudinal retrospective multicenter study. Bone Marrow Transplantation, null. https://doi.org/10.1038/s41409-023-02157-3

Ruggeri, Annalisa, de Wreede, Liesbeth C., Müller, Carlheinz R., Crivello, Pietro, Bonneville, Edouard F., Petersdorf, Effie W., Socié, Gerard, Dubois, Valérie, Niittyvuopio, Riitta, Peräsaari, Juha, Yakoub-Agha, Ibrahim, Cornelissen, Jan J., Wieten, Lotte, Gedde-Dahl, Tobias, Forcade, Edouard, Crawley, Charles R., Marsh, Steven G.E., Gandemer, Virginie, Tholouli, Eleni, et al. (2023). Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica, 108, 645–652. https://doi.org/10.3324/haematol.2021.280055

Sava M, Bättig V, Gerull S, Passweg JR, Khanna N, Garzoni C, Gerber B, Mueller NJ, Schanz U, Berger C, Chalandon Y, van Delden C, Neofytos D, Stampf S, Franzeck FC, Weisser M, & Swiss Transplant Cohort Study. (2023). Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates (Patent No. 1). 58(1), Article 1. https://doi.org/10.1038/s41409-022-01851-y

Spyridonidis, A., Labopin, M., Gedde-Dahl, T., Ganser, A., Stelljes, M., Craddock, C., Wagner-Drouet, E. M., Versluis, J., Schroeder, T., Blau, I. W., Wulf, Gerald. G., Dreger, P., Olesen, G., Sengeloev, H., Kröger, N., Potter, V., Forcade, E., Passweg, J., de Latour, R. P., et al. (2023). Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, null. https://doi.org/10.1038/s41409-023-02139-5

Stetka, Jan, Usart, Marc, Kubovcakova, Lucia, Rai, Shivam, Rao, Tata Nageswara, Sutter, Joshua, Hao-Shen, Hui, Dirnhofer, Stefan, Geier, Florian, Bader, Michael S., Passweg, Jakob R., Manolova, Vania, Dürrenberger, Franz, Ahmed, Nouraiz, Schroeder, Timm, Ganz, Tomas, Nemeth, Elizabeta, Silvestri, Laura, Nai, Antonella, et al. (2023). Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood, 141(17), 2127–2140. https://doi.org/10.1182/blood.2022017976

Warthmann, Andrea, Holbro, Andreas, Buser, Andreas, Schefer, Stefan, Degen Kellerhals, Sabine, Ravelli, Miriam, Passweg, Jakob, Stussi, Georg, & Halter, Jörg. (2023). BleedHD—a new electronic assessment tool for grading chronic graft-versus-host disease validated in a multicenter and multiprofessional setting. Bone Marrow Transplantation, 58(5), 613–615. https://doi.org/10.1038/s41409-023-01945-1

Forestieri G, Terzi di Bergamo L, Deodato M, Frustaci AM, Moia R, Deambrogi C, Rasi S, Autore F, Merli M, Mattarucchi R, Fahrni G, Scarfo’ L, Gussetti D, Bulian P, Zanatta A, Spina V, Bruscaggin A, Pini K, Piffaretti D, et al. (2022). Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia (Patent No. 5). 40(5), Article 5. https://doi.org/10.1002/hon.3032

Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, Sica S, Vydra J, Fanin R, Diez-Martin JL, Bulabois CE, Stölzel F, Busca A, Jindra P, Koc Y, Chevallier P, Forcade E, Rösler W, Passweg J, et al. (2022). Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. Bone Marrow Transplantation, 57(11), 1657–1663. https://doi.org/10.1038/s41409-022-01781-9

Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, Sica S, Vydra J, Fanin R, Diez-Martin JL, Bulabois CE, Stölzel F, Busca A, Jindra P, Koc Y, Chevallier P, Forcade E, Rösler W, Passweg J, et al. (2022). Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9) (Patent No. 11). 57(11), Article 11. https://doi.org/10.1038/s41409-022-01856-7

Kirsch M, Stehle GT, Konantz M, Passweg J, Dirnhofer S, Meyer SC, & Hartmann K. (2022). Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis. Journal of Allergy and Clinical Immunology: In Practice, 10(11), 3035–3038. https://doi.org/10.1016/j.jaip.2022.07.014

Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, et al. (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Frontiers in Oncology, 12, 999822. https://doi.org/10.3389/fonc.2022.999822

Maffini E, Labopin M, Beelen DW, Kroeger N, Arat M, Wilson KMO, Bay JO, Ganser A, Martin H, Passweg J, Kottaridis PD, Yakoub-Agha I, Porras RP, Wagner EM, Esteve J, Lanza F, Nagler A, & Mohty M. (2022). Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 57(10), 1556–1563. https://doi.org/10.1038/s41409-022-01748-w

Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, Finke J, Ganser A, Einsele H, Kröger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Blau IW, Elmaagacli A, Schäfer-Eckart K, Platzbecker U, et al. (2022). Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/ Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis (Patent No. 19). 28(19), Article 19. https://doi.org/10.1158/1078-0432.CCR-22-0809

Luque Paz, D., Bader, M. S., Nienhold, R., Rai, S., Almeida Fonseca, T., Stetka, J., Hao-Shen, H., Mild-Schneider, G., Passweg, J. R., & Skoda, R. C. (2022). Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2022.09.24.509318

Dalla Via V, Stelmes A, Recher M, Arranto C, Junker T, Matteazzi F, Heim D, Passweg JR, Medinger M, & van den Berg J. (2022). Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults with Primary Immunodeficiency: A Case Series (Patent No. 9). 42(9), Article 9. https://doi.org/10.21873/anticanres.15952

Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D, Di Grazia C, Koc Y, Potter V, Chevallier P, Lopez-Corral L, Wu D, Mielke S, Maertens J, Meijer E, Huynh A, Passweg J, Luft T, Pérez-Simón JA, et al. (2022). Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer Journal, 12(9), 140. https://doi.org/10.1038/s41408-022-00729-y

Medinger M, Junker T, Heim D, Tzankov A, Jermann PM, Bobadilla M, Vigolo M, Lehal R, Vogl FD, Bauer M, & Passweg J. (2022). CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL. (Patent No. 3). 3(3), Article 3. https://doi.org/10.1002/jha2.510

Weisser, M., Sava, M., Baettig, V., Gerull, S., Passweg, J., Khanna, N., Garzoni, C., Gerber, B., Mueller, N., Schanz, U., Berger, C., Chalandon, Y., Delden, C. v., Neofytos, D., Stampf, S., & Franzeck, F. (2022, July 14). Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study [Posted-content]. Research Square Platform LLC. https://doi.org/10.21203/rs.3.rs-1828291/v1

Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, Finke J, Passweg J, Cornelissen J, Schub N, Veelken JH, Beguin Y, Wilson K, Zuckerman T, Hunault-Berger M, Lioure B, Porras RP, Turlure P, Kerre T, et al. (2022). Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 57(7), 1072–1078. https://doi.org/10.1038/s41409-022-01686-7

Beerlage A, Leuzinger K., Valore L, Mathew R, Junker T, Drexler B, Passweg JR, Hirsch HH, & Halter J. (2022). Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease, 24(3), e13828. https://doi.org/10.1111/tid.13828

Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, et al. (2022). Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. Bone Marrow Transplantation, 57(6), 896–902. https://doi.org/10.1038/s41409-021-01555-9

Seydoux C, Battegay R, Halter J, Heim D, Rentsch KM, Passweg JR, & Medinger M. (2022). Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 57(6), 903–910. https://doi.org/10.1038/s41409-022-01641-6

Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, et al. (2022). One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 107(5), 1045–1053. https://doi.org/10.3324/haematol.2021.279189

Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, Mohty M, Neven B, Peffault de Latour R, Perić Z, Snowden JA, Yakoub-Agha I, Sureda A, Kröger N, & European Society for Blood and Marrow Transplantation (EBMT). (2022). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 57(5), 742–752. https://doi.org/10.1038/s41409-022-01604-x

Fattinger N, Roth JA, Baldomero H, Stolz D, Medinger M, Heim D, Heim D, Tamm M, Halter JP, Passweg JR, & Kleber M. (2022). External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study. HemaSphere, 6(4), e704. https://doi.org/10.1097/HS9.0000000000000704

Bräutigam M, Volken T, Plattner A, Passweg JR, Halter JP, Drexler B, Heim D, Schaub S., Buser AS, Infanti L., & Holbro A. (2022). Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation. Transfusion and Apheresis Science, 61(2), 103301. https://doi.org/10.1016/j.transci.2021.103301

Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D’Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, et al. (2022). Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 7(2), 100403. https://doi.org/10.1016/j.esmoop.2022.100403

Drozd-Sokołowska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H, Byrne J, Bulabois CE, Passweg J, Ozkurt ZN, Schroyens W, Lioure B, Colorado Araujo M, Poiré X, Van Gorkom G, et al. (2022). Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT. Bone Marrow Transplantation, 57(4), 633–640. https://doi.org/10.1038/s41409-022-01592-y

Héritier J, Medinger M, Heim D, Baldomero H, Arranto C, Halter JP, Passweg JR, & Kleber M. (2022). Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study. Bone Marrow Transplantation, 57(4), 613–619. https://doi.org/10.1038/s41409-022-01598-6